Trial Profile
A Phase 2 Study of GI-6207 in Patients With Recurrent Medullary Thyroid Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 05 Oct 2021
Price :
$35
*
At a glance
- Drugs GI 6207 (Primary)
- Indications Adenocarcinoma; Bone metastases; Thyroid cancer
- Focus Therapeutic Use
- Sponsors ImmunityBio
- 22 Oct 2019 Planned primary completion date changed from 1 Sep 2019 to 31 Dec 2019.
- 20 Dec 2017 Status changed from recruiting to active, no longer recruiting.
- 24 Aug 2017 Planned End Date changed from 1 Jan 2019 to 1 Mar 2020.